Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with KRAS Wild-type Metastatic Colorectal Cancer: A Meta-analysis

BACKGROUND: Cetuximab 500 mg/m(2) biweekly (Q2W) plus chemotherapy is commonly used and recommended by NCCN guidelines. This meta-analysis compares efficacy and safety between Q2W versus weekly (Q1W) cetuximab dosing. METHODS: A systematic literature review was performed on Pubmed and RightFind (200...

Descripción completa

Detalles Bibliográficos
Autores principales: Parikh, Aparna R, Gonzalez-Gugel, Elena, Smolyakova, Natalia, Jen, Min-Hua, Toms, Nikki, Lin, Yong, Kim, Jong Seok, Kopetz, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Gastrointestinal Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074967/
https://www.ncbi.nlm.nih.gov/pubmed/35522557
http://dx.doi.org/10.1093/oncolo/oyab030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074967/
https://www.ncbi.nlm.nih.gov/pubmed/35522557
http://dx.doi.org/10.1093/oncolo/oyab030

Ejemplares similares